| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
NF-κB and MAPK signaling pathways; lipid metabolism-mediating proteins. Pinostrobin chalcone interferes with multiple cellular signaling pathways such as NF-κB and MAPK, contributing to its anti-proliferative and pro-apoptotic effects on cancer cells. It inhibits the activity of lipid metabolism-mediating proteins, leading to reduced lipid accumulation in adipocytes. Its interactions with enzymes involved in apoptosis highlight its role in modulating metabolic flux and promoting cell death in cancer cells.
|
|---|---|
| ln Vitro |
Pinostrobin chalcone is a potent natural cytotoxic compound against MDA-MB-231 breast cancer cells (IC₅₀ = 20.42 ± 2.23 μg/mL) and HT-29 colon cancer cells (IC₅₀ = 22.51 ± 0.42 μg/mL). It also displays remarkable cytotoxic activity against KB (IC₅₀ = 6.2 μg/mL), MCF7 (IC₅₀ = 7.3 μg/mL), and Caski (IC₅₀ = 7.7 μg/mL) cancer cells. The compound inhibits lipid metabolism-mediating proteins, reducing lipid accumulation in adipocytes. It interferes with NF-κB and MAPK signaling pathways.
|
| ln Vivo |
In vivo studies of pinostrobin chalcone are limited. As a chalcone with broad-spectrum bioactivity including anticancer, anti-inflammatory, and antimicrobial effects, it has potential for evaluation in animal models of cancer, inflammation, and infection. Its anti-proliferative and pro-apoptotic effects on cancer cells suggest potential antitumor efficacy. Further in vivo studies are needed to characterize its pharmacokinetic and pharmacodynamic properties.
|
| Enzyme Assay |
Non-cell-based assays for pinostrobin chalcone include enzyme inhibition studies to assess its effects on NF-κB and MAPK signaling components. Lipid metabolism enzyme assays can be performed to assess inhibition of lipid metabolism-mediating proteins. Standard analytical methods including HPLC, NMR, and mass spectrometry are used for compound characterization and purity assessment.
|
| Cell Assay |
Cell-based assays for pinostrobin chalcone use various cancer cell lines including MDA-MB-231, HT-29, KB, MCF7, and Caski cells. Cells are treated with the compound at various concentrations, and cell viability is measured using MTT or SRB assays. Apoptosis is evaluated by flow cytometry using Annexin V/PI staining. For adipocyte studies, lipid accumulation is assessed using Oil Red O staining. Signaling pathway modulation is assessed by Western blot.
|
| Animal Protocol |
In vivo studies of pinostrobin chalcone are limited. Based on its biological activities, potential animal models include: tumor xenograft models for anticancer evaluation; models of metabolic disorders for evaluating effects on lipid metabolism; and infection models for antimicrobial evaluation. Standard protocols for these models involve administration of the compound followed by measurement of relevant endpoints.
|
| ADME/Pharmacokinetics |
Pinostrobin chalcone has a molecular formula of C₁₆H₁₄O₃ and a molecular weight of approximately 254.28 g/mol. It is a chalcone analog isolated from Mucuna pruriens and found in Lindera umbellata. The compound is a flavonoid precursor. It should be stored under recommended conditions. It is intended for research use only.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for pinostrobin chalcone are limited. The compound exhibits potent cytotoxic activity against various cancer cell lines with IC₅₀ values ranging from 6.2 to 22.51 μg/mL. Standard laboratory safety practices should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Pine chalcones are a type of chalcone compound. They have been reported to be found in bees, turmeric, and other organisms with relevant data.
Pinostrobin chalcone is a chalcone analog isolated from Mucuna pruriens and found in Lindera umbellata. It is a potent natural cytotoxic compound against MDA-MB-231 (IC₅₀ = 20.42 μg/mL), HT-29 (IC₅₀ = 22.51 μg/mL), KB (IC₅₀ = 6.2 μg/mL), MCF7 (IC₅₀ = 7.3 μg/mL), and Caski (IC₅₀ = 7.7 μg/mL) cancer cells. It inhibits lipid metabolism-mediating proteins and interferes with NF-κB and MAPK signaling pathways. It has broad-spectrum bioactivity for cancer, infection, and inflammation-related disorders and is for research use only. |
| Molecular Formula |
C16H14O4
|
|---|---|
| Molecular Weight |
270.28
|
| Exact Mass |
270.089
|
| CAS # |
18956-15-5
|
| PubChem CID |
5316793
|
| Appearance |
Light yellow to orange solid
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
521.1±50.0 °C at 760 mmHg
|
| Melting Point |
163.5 - 164.5 °C
|
| Flash Point |
198.0±23.6 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.658
|
| LogP |
4.4
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
20
|
| Complexity |
334
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OC1C=C(OC)C=C(O)C=1C(=O)/C=C/C1C=CC=CC=1
|
| InChi Key |
CUGDOWNTXKLQMD-BQYQJAHWSA-N
|
| InChi Code |
InChI=1S/C16H14O4/c1-20-12-9-14(18)16(15(19)10-12)13(17)8-7-11-5-3-2-4-6-11/h2-10,18-19H,1H3/b8-7+
|
| Chemical Name |
(E)-1-(2,6-dihydroxy-4-methoxyphenyl)-3-phenylprop-2-en-1-one
|
| Synonyms |
Pinostrobin chalcone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (369.99 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.25 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6999 mL | 18.4993 mL | 36.9987 mL | |
| 5 mM | 0.7400 mL | 3.6999 mL | 7.3997 mL | |
| 10 mM | 0.3700 mL | 1.8499 mL | 3.6999 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
